Our pipeline consists of highly differentiated molecules that were designed and optimized to effectively block key oncogenic pathways in hematological malignancies and solid tumors to address important unmet needs in patients with cancer.
We are advancing a diverse pipeline of first-in-class or potentially best-in-class agents for hard-to-treat solid tumors and hematologic malignancies. This includes the industry’s leading SMARCA-targeted pipeline.
Our differentiation strategy is to design and optimize each of our small molecule therapeutics to possess specific properties that have the potential to benefit patients:
- PRT3789 (SMARCA2), we sought high selectivity over SMARCA4 to elicit synthetic lethality using a targeted protein degrader approach
- For PRT2527 (CDK9), we optimized for superior selectivity over previously developed CDK9i to improve tolerability
| Program | Potential Indications | Discovery | Phase 1 | Phase 2/3 | Upcoming Milestones |
|---|---|---|---|---|---|
| PR-01 | |||||
| Lead SMARCA2 Degrader (IV) |
SMARCA4-mutated NSCLC & other cancers | PRT3789 | Phase I Initial Proof-of-Concept Data in 2H 2024 | ||
| Oral SMARCA2 Degrader |
SMARCA4-mutated NSCLC & other cancers | PRT7732 | Phase I Start Anticipated in 2H 2024 | ||
| SMARCA2/4 Precision ADCs* |
Broad range of cancers (heme & solid tumors) | Expand SMARCA Portfolio to Address Cancers Without SMARCA4 Mutations | |||
| Next-Gen CDK9 Selective Inhibitor |
Myeloid and B-cell malignancies | PRT2527 | Phase I Initial Proof-of-Concept Data in 2H 2024 | ||
| Discovery Engine | Hard-to-treat cancers, “undruggable” targets, high unmet need | Deliver a First- or Best-in-Class New Program Every 12-18 Months | |||
| Precision ADCs* | Broad range of cancers (heme & solid tumors) | Co-Develop Up to 5 Novel ADCs/DACs in Total | |||
| PR-01 | Lead SMARCA2 Degrader (IV) PRT3789 | |
| SMARCA4-mutated NSCLC & other cancers | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Phase I Initial Proof-of-Concept Data in 2H 2024 | ||
| Oral SMARCA2 Degrader PRT7732 | ||
| SMARCA4-mutated NSCLC & other cancers | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Phase I Start Anticipated in 2H 2024 | ||
| SMARCA2/4 Precision ADCs* | ||
| Broad range of cancers (heme & solid tumors) | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Expand SMARCA Portfolio to Address Cancers Without SMARCA4 Mutations | ||
| Next-Gen CDK9 Selective Inhibitor PRT2527 | ||
| Myeloid and B-cell malignancies | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Phase I Initial Proof-of-Concept Data in 2H 2024 | ||
| Discovery Engine | ||
| Hard-to-treat cancers, “undruggable” targets, high unmet need | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Deliver a First- or Best-in-Class New Program Every 12-18 Months | ||
| Precision ADCs* | ||
| Broad range of cancers (heme & solid tumors) | ||
Discovery Phase 1 Phase 2 | ||
| Upcoming Milestones: Co-Develop Up to 5 Novel ADCs/DACs in Total | ||
*In partnership with